Jama Bogart
Nurse Practitioner · Nevada, MONPI 1801972682
Payments from drug & device makers
Across 117 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$364
- AbbVie$280
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$238
- Vanda Pharmaceuticals Inc.$164
- Axsome Therapeutics, Inc.$142
- Johnson & Johnson$136
- plus $870 from 19 others
What the payments were for
- Food & beverage$2,194100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $364 |
| AbbVie | 16 | $280 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $238 |
| Vanda Pharmaceuticals Inc. | 7 | $164 |
| Axsome Therapeutics, Inc. | 8 | $142 |
| Johnson & Johnson | 5 | $136 |
| AstraZeneca | 9 | $134 |
| Novo Nordisk | 8 | $124 |
| Indivior Inc. | 5 | $121 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $112 |
| Lilly USA, LLC | 4 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Amgen | 2 | $44 |
| Pfizer | 2 | $33 |
| Alkermes, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Vertex | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Merck | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
| Medtronic | 1 | $12 |
How this compares
$2,194 in reported general payments places this provider in the 85th percentile of 1,898 nurse practitioner providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 30 | $45,018 |
| VraylarCariprazine Hcl | 25 | $37,530 |
| OzempicSemaglutide | 19 | $30,941 |
| Invega SustennaPaliperidone Palmitate | 13 | $29,775 |
| MounjaroTirzepatide | 26 | $27,858 |
| TrintellixVortioxetine Hydrobromide | 29 | $15,235 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $14,291 |
| JardianceEmpagliflozin | 14 | $10,357 |
| EliquisApixaban | 17 | $10,005 |
| Clomipramine Hcl | 45 | $8,724 |
| LinzessLinaclotide | 12 | $6,729 |
| MyrbetriqMirabegron | 14 | $5,862 |
| Chlorpromazine Hcl | 27 | $4,549 |
| Bromocriptine Mesylate | 14 | $4,534 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $364 | $45,01830 claims |
| AbbVieVraylar, Linzess | $280 | $44,25837 claims |
| Novo NordiskOzempic | $124 | $30,94119 claims |
| Johnson & JohnsonInvega Sustenna | $136 | $29,77513 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $61 | $29,193110 claims |
| PfizerEliquis | $33 | $10,00517 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $5,86214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,898 nurse practitioner providers in Missouri.
Other nurse practitioner in Nevada
- Aeron SheffieldChesterfield$269K
- Rachel ImperatoOsage Beach$260K
- Matthew BrunsBridgeton$126K
- Michelle DickensSpringfield$59K
- Robert HafnerKansas City$47K
- Tracey CarpenterChesterfield$47K
- Laura GrantSaint Charles$34K
- Courtney JefferyKansas City$24K
- Carrie Roth BettlachSaint Louis$21K
- Amanda HumbersFarmington$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.